Eudamed Releases Timetable to Update the EU’s Medical Device Regulation and in Vitro Diagnostic Regulation
Eudamed (EU databank medical devices), has released a timetable for the expected completion of legislation towards the amended Medical Device Regulation (MDR) and In Vitro Diagnostic Regulation (IVDR) in the 3rd steering committee.
In the final draft of the amended regulations, the chemical requirements are clearly defined. In particular, MDR points out that labelling is necessary if a device, part or material contains CMR1 1A, 1B or EDCs2 higher than 0.1% (w/w). Even information or precautionary measures shall be given in the instructions for use for certain groups considered particularly vulnerable to such substances and/or materials.
The new EU MDR and IVDR have been discussed since 2012. After a long process, Eudamed released a timetable related to the expected completion of legislation for the amendment of MDR and IVDR in the 3rd steering committee, as below. According to the following timetable, the official version of the amended MDR and IVDR will probably be published by the end of May 2017.
- At the end of January 2017 the English versions of the new MDR and IVDR are expected to be ready
- By the middle of February 2017, English versions as well as the translations into all European Union languages will be distributed among stakeholders
- By the beginning of March 2017 the Council is expected to accept this version
- By the beginning of April 2017 the European Parliament should adopt the Regulations
- Formal publication would then take place at the end of April 2017
- Official entry into power by the end of May 2017
- The MDR would then be applicable from the end of May 2020
- The IVDR would then be applicable from the end of May 2022
On February 22, 2017 Eur-lex released the final draft of the amended MDR  and IVDR. In the section 10.4.1 and 10.4.5 of draft MDR and section 10.3 of draft IVDR the chemical requirements are listed. Additionally, MRD includes some special guidelines on phthalates and CMR or endocrine disruption substances. MDR indicates that a label is necessary if a device, part or material contains CMR 1A, 1B or EDCs in a concentration higher than 0.1% (w/w). Information or precautionary measures shall be given in the device instructions for use with or treatment of children, treatment of pregnant or breastfeeding women, treatment of other patient groups considered particularly vulnerable to such substances and/or materials in order to prevent harm from CMR 1A, 1B or EDCs. More details can be found in the following table 1.
|Final draft of
amended medical device regulation
shall only contain the following substances in a concentration that is above 0,1 % (w/w) where justified pursuant to Section 10.4.2, then a labelling on devices or packaging needs to be accomplished according to section 10.4.5.
Section 10.4.5 labelling
|Final draft of amended IVD
2 EDCs: Endocrine disrupting chemicals
3 CLP: Classification, Labelling and Packaging of substances and mixtures
4 REACH: Registration, Evaluation, Authorization and Restriction of Chemicals
5 BPR: Biocidal Product Regulation
For more information, please contact:
Certification and Business Enhancement
Tel: (852) 2765 3620
SGS is the world’s leading inspection, verification, testing and certification company. SGS is recognized as the global benchmark for quality and integrity. With more than 90,000 employees, SGS operates a network of over 2,000 offices and laboratories around the world.